Articles tagged with Drug Studies
A study by Martin-Luther-University Halle-Wittenberg found a link between high levels of IGF2BP2 and faster-growing bowel cancer tumours with chemotherapy resistance. The protein's role in cell growth and metabolism may lead to the development of new diagnostic procedures and therapeutic strategies.
Researchers from McGill University and Ontario Tech University examine the drivers of specialty drug diffusion. They propose a framework that suggests clinical studies affect the diffusion through a multi-stage scientific evidence production process. The study finds that marketing activities have no significant effect on prescriptions.
The use of psychedelics in mental health treatment is gaining traction, but concerns about patient safety and regulation need to be addressed. Psychedelic-assisted therapy shows promise in treating conditions like depression and PTSD, but more research is needed on dosages, settings, and guidelines.
The Better Together trial partners with community organizations and sites to provide buprenorphine treatment, reducing distance for patients and offering peer support in familiar environments. Researchers aim to address barriers such as stigma, misunderstandings about addiction, and bias against certain treatments.
A new study found that the serotonin booster prucalopride increased functional brain connectivity in healthy adults, particularly between cognitive networks. The results suggest that prucalopride may improve cognitive function and have therapeutic potential for depression patients.
A machine-learning study has found that individual characteristics, including age and weight, determine which drug combinations most effectively reduce COVID-19 recurrence rates. The study used real-world data from a hospital in China and identified unique treatment combinations for different demographic groups.
A powerful new stem cell technique has enabled large-scale studies of the relationship between human genetics and biology, accelerating research and potential personalized treatments.
A large-scale randomized clinical trial found that metformin prevents the development of long COVID. Over 1,100 participants reported on their symptoms for up to 10 months after initial COVID-19 diagnosis. The study suggests metformin could have significant public health implications as a preventive measure.
A decision analytical model study found that sustained public health interventions can reduce opioid-related overdose deaths. Implementing medications for opioid use disorder and increasing naloxone supply were key factors in reducing death rates.
Young adults' past-year use of non-LSD hallucinogens increased from 3.4% in 2018 to 6.6% in 2021, raising public health concerns. The study found that male and white young adults used these substances more frequently.
A retrospective study found a 24% response rate to Docetaxel among patients with stage IV non-small cell lung cancer who experienced progression on immunotherapy. The median progression-free survival was 3 months, suggesting chemotherapy may still play an important role in treatment after immunotherapy failure.
Researchers at the University of Gothenburg found that semaglutide, a diabetes medication, significantly reduced alcohol intake and relapse-like drinking in rats. This study suggests that semaglutide may be effective in treating alcohol dependence, particularly for individuals with both obesity and diabetes.
Two studies investigate long-term consequences of COVID-19, identifying potential drug targets for treating chronic disease. Researchers found novel pathways in the lungs and immune system that may lead to effective treatment options, including therapies targeting immune dysfunction and mucous cell differentiation.
Researchers at UCSF tested a nitroglycerin patch for treating menopausal women experiencing severe hot flashes. The study found short-term improvements, but benefits did not last past 12 weeks, with some side effects reported.
A supervised hospital walking program has been shown to reduce nursing facility admissions for older adults by lowering the proportion of patients discharged to skilled nursing facilities from 13% to 8%. However, low participation rates and limited impact on length of stay or inpatient falls were noted.
Erdafitinib achieves tumor-agnostic benefits across 16 cancer types, including urothelial, lung, and other cancers. The trial demonstrated a disease control rate of 73.7% and clinical benefit rate of 45.6%, with notable improvements in pancreatic and cholangiocarcinoma patients.
The study found an objective response rate of 61.3% with a median duration of response of 22.1 months in patients with high HER2 expression. The treatment showed promise in a significant unmet area of clinical need, providing a new option for patients with hard-to-treat HER2-positive cancers.
A phase 3 clinical trial by Dana-Farber Cancer Institute has shown vorasidenib significantly prolongs progression-free survival and delays radiation and chemotherapy for patients with Grade 2 IDH-mutant glioma. Treatment with vorasidenib can delay cognitive dysfunction in patients and preserve their quality of life.
A new targeted therapy drug vorasidenib has been shown to extend treatment time without worsening glioma in people with IDH1 and IDH2 mutations. The study suggests a possible new treatment option for slow-growing but deadly brain tumors, delaying chemotherapy and radiation.
A phase I study found significant clinical benefit of the ADC luveltamab tazevibulin in patients with recurrent ovarian cancer expressing high levels of folate receptor alpha, with an overall response rate of 37.5% and a 44% response rate at higher doses.
A Phase II trial led by MD Anderson Cancer Center showed that zanidatamab achieved a 41% confirmed objective response rate and durable responses in HER2-positive biliary tract cancer. This represents the largest study of a HER2-targeted drug in BTC, providing evidence for its potential as a new treatment option.
A retrospective cohort study of over 66,000 older adults found that intensive antihypertensive treatment during hospitalization was linked to greater risk of adverse events. Treating asymptomatic elevated blood pressure in hospitalized patients may not be necessary and could lead to overtreatment.
A new clinical trial found that low-dose atropine eye drops are effective in slowing the progression of nearsightedness in children. The treatment showed significant improvements in limiting eyeglass prescription changes and inhibiting elongation of the eye, with a daily drop in each eye being enough to make a difference.
A study suggests that ketamine nasal spray is a convenient alternative to intravenous infusion for treating refractory chronic migraine. The treatment showed promise in reducing daily headaches and improving quality of life, with most participants reporting 'very effective' results.
Researchers found that a combination of amyloid burden and blood markers of abnormal astrocyte activation can predict Alzheimer's disease progression. Testing for these biomarkers may help identify patients at risk, enabling earlier diagnosis and treatment.
A Canadian study found that eliminating out-of-pocket medication expenses for patients with cost-related nonadherence results in lower healthcare spending over three years. The analysis suggests that reducing medication costs could lead to significant savings in the overall healthcare system.
Researchers at UTHealth Houston are investigating the role of fibrin and fibrinogen in traumatic brain injury and hemorrhagic shock. The four-year grant will fund Phase II of a stem cell clinical trial evaluating whether mesenchymal stem cells reduce chronic neuroinflammatory response to traumatic brain injury.
The Alzheimer's disease development pipeline has seen an increase in promising therapies and pharma investment, driving momentum in clinical trials. The pipeline currently has 187 clinical trials, with recent FDA approvals for two disease-modifying therapies, and more on the way.
Researchers have identified a novel model and therapy to mitigate the development of REM sleep behavior disorder, which affects over 3 million Americans. Dual orexin receptor antagonists have been shown to significantly reduce dream enactment behaviors, providing a promising new treatment option.
Researchers developed an experimental drug, 32-134D, that inhibits HIF protein levels, reducing blood vessel production and leakiness in diabetic eyes. The study shows promising results in both human cell models and mice, suggesting a safer therapeutic approach for diabetic eye disease.
Researchers found that isosorbide mononitrate and cilostazol can safely improve debilitating outcomes after lacunar stroke. The two drugs were even more effective when used in combination, with participants showing significant improvements in thinking and memory skills, as well as quality of life.
A case study published in the Journal of Alzheimer's Disease reveals that lecanemab can lead to therapy-induced Aβ phagocytosis and multifocal intracerebral hemorrhage, highlighting a potential risk of brain damage and death. The study suggests that better biomarkers are needed to assess the extent of cerebral amyloid angiopathy.
A clinical trial of 403 patients found that ketamine treatment was non-inferior to ECT for treating non-psychotic treatment-resistant depression. Ketamine showed fewer side effects than ECT, with improved depressive symptoms and quality of life.
Researchers have developed new methods to analyze dry-coated drug particles using 3D Raman mapping, which can effectively slow down dissolution rates. Another study introduces a novel technique for detecting complex traditional Chinese medicines, preventing adulteration and counterfeiting.
Researchers have found a compound that can prevent cisplatin-induced renal toxicity and improve the outcomes of cancer treatment. The aromatic ketone 2',4',6'-trihydroxyacetophenone (THA) inhibits the CCBL1-mediated metabolism of cisplatin, reducing its toxic effects without affecting its potency.
A clinical trial combining TVB-2640 and bevacizumab showed a six-month progression-free survival improvement in patients with recurrent high-grade glioblastoma, warranting further study. The treatment's side effects were mild, but the overall survival of participants was not statistically significant compared to historic controls.
Researchers have developed a pharmacological treatment that improves cardiac function in patients with stiff-heart syndrome, a condition caused by amyloid protein deposition. The new drug reduces amyloid protein deposits and shows promise in reversing established disease symptoms.
A recent study published in The Lancet Neurology found that valbenazine significantly reduces chorea symptoms in patients with Huntington’s disease. The Phase III trial showed improvement as early as the second week of treatment, with consistently greater benefits compared to a placebo.
A multicentre, one-year real-world study found semaglutide effective for weight loss in patients with overweight and obesity, with 82% losing over 5% body weight. The medication also improved metabolic parameters, including blood pressure and cholesterol levels.
A new analysis of the SURMOUNT-1 study shows that tirzepatide improves body composition across a range of adult age groups, with significant reductions in fat mass. The treatment also results in a clinically meaningful improvement in body composition, with only one-quarter of weight lost being lean mass.
A large-scale clinical trial has found that spironolactone is an effective treatment for persistent acne in women, offering an alternative to antibiotics. The study, funded by the National Institute for Health and Care Research, recruited over 400 women with acne that had persisted for more than six months.
Researchers at Dartmouth Cancer Center found that alternating estrogen stimulation and anti-estrogen therapy is an effective treatment for patients with metastatic or advanced ER+ breast cancer. The POLLY trial showed that 42% of patients experienced tumor stabilization, while no patients discontinued treatment due to side effects.
Researchers developed a novel combination therapy that eradicates tumors in select patients, with prolonged survival rates. The therapy has shown promise in treating glioblastoma, a notoriously difficult-to-treat primary brain cancer.
The FDA approved Recarbrio, an antibiotic 40 times more expensive than a generic alternative, without adequate clinical trials showing substantial evidence of effectiveness. The approval has raised concerns that the agency's standards are being bypassed, and regulatory flexibility may have played a role in the decision.
A Phase 1 clinical trial has started to test the safety and tolerability of an experimental oral drug called HOPO 14-1 in healthy adults. The study aims to determine how the drug removes radioactive contaminants from the body, which can occur after nuclear accidents or exposure to dirty bombs.
A Phase I/II clinical trial combining intratumoral delivery of an engineered oncolytic virus with subsequent immunotherapy improved survival outcomes in a subset of patients with recurrent glioblastoma. The study demonstrated the combination was well-tolerated, with no dose-limiting toxicities.
Clinical studies with children as participants often require more time, people, and resources than initially budgeted. The study found that pediatric clinical studies cost 59% more on average than the initial proposal, highlighting a need for accurate budgeting.
A team of researchers is exploring the potential of HDAC inhibitors to treat sickle cell disease by reactivating the fetal hemoglobin gene. Early evidence suggests that panobinostat, a specific inhibitor, can increase fetal hemoglobin levels in red blood cells and mouse models.
The study used magnetic resonance imaging (MRI) to measure acute pressure changes inside the heart, discovering that pressure increases when patients receive a specific medication called adenosine. This technology can help doctors better diagnose and monitor patients with heart disease and heart failure.
Researchers used cancer proteomics data to identify gene candidates for therapeutic targeting, focusing on protein kinases in uterine endometrial cancer cells. Public molecular resources and multi-omics data analysis can prioritize genes of interest for future studies.
A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer, with patients experiencing significantly improved progression-free survival. The median PFS was 11.3 months for those on nivolumab and ipilimumab alone, compared to not yet reached in the three-drug group.
A new study by Harvard T.H. Chan School of Public Health found significant racial inequalities in treatment for opioid use disorder, with White patients receiving medication up to 80% more frequently than Black and Hispanic patients. Despite similar numbers of healthcare visits, disparities persist.
Trials of Pfizer's maternal RSV vaccine suggest a possible increase in preterm births, prompting experts to call for further analysis and post-approval monitoring. The vaccine aims to protect infants from severe RSV illness, but its safety concerns have raised eyebrows.
A Cochrane review found that most antidepressants used to manage chronic pain lack sufficient evidence of their effectiveness, with only duloxetine showing reliable pain relief. The review also revealed that harms from many commonly recommended drugs have not been well studied, posing a global public health concern.
Researchers at McMaster University have found that solriamfetol is the most effective treatment for excessive daytime sleepiness (EDS) in individuals with obstructive sleep apnea (OSA). A systematic review of 14 clinical trials and analysis of data from various databases revealed solriamfetol to be the best option.
The study shows that zolbetuximab delays tumor progression and improves overall survival by 25% compared to chemotherapy alone. Patients with CLDN18.2-positive tumors responded well to the treatment, indicating a new clinically relevant biomarker for gastric cancer.
A retrospective cohort study of U.S. veterans found that adding a GLP1 receptor agonist to diabetes treatment reduced the risk of major adverse cardiovascular events and heart failure hospitalization by about 20% compared to DPP4 inhibitors. The study's findings will aid clinicians in choosing a diabetes drug regimen for older patients.
Scientists have developed a new method to deliver genetic information to stem cells using nanoparticles coated with a specific polymer, enabling more efficient control over cellular differentiation. This innovation has the potential to improve the efficiency and effectiveness of regenerative medicine treatments.
KNT-127 exhibits anti-stressing and anti-depressant effects in mice, improving social interaction and reducing stress-induced hormone levels. The agent suppresses neuronal inflammation and newborn death without affecting neurogenesis.
A sharp increase in colchicine's price led to a 17% drop in its use and worsened disease control in gout patients. Patients turned to alternative medications with potentially different side effects, resulting in increased emergency department visits and specialist consultations.